N onalcoholic fatty liver disease (NAFLD) is currently recognized as one of the most prevalent etiologies of chronic liver disease worldwide. (1, 2) NAFLD is estimated to afflict approximately 80-100 million adults in the United States. NAFLD is broadly classified into nonalcoholic fatty liver, the non-progressive form of NAFLD, and nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD. Patients with NASH have a higher risk of progression to cirrhosis and hepatocellular carcinoma and are at an increased risk of liver-related morbidity and mortality. (3) Abbreviations: AE, additive genetics and unique environment effects; MRE, MR-elastography; MRI-PDFF, magnetic-resonance-imaging protondensity-fat-fraction; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis.
Previous seminal studies have shown that NAFLD is a heritable trait. (4, 5) In addition, we have demonstrated that hepatic steatosis is heritable and has a shared gene-effect with metabolic risk factors and liver fibrosis using a twin study design. (6, 7) Although genome-wide association studies (GWAS) have identified genetic variants associated with NAFLD located on PNPLA3 (8) and TM6SF2 (9) genes, these common risk alleles do not account for all of the variance observed in NAFLD. (10) Given the epidemic increase of NAFLD and its association with an increase of morbidity and mortality, there is a need to better characterize the heritability of NAFLD to understand its pathogenesis, identify potential therapeutic targets, and improve the screening of the patients who are at a higher risk of progression to cirrhosis.
Metabolome profiling has provided new insights into the molecular mechanisms of diseases including NAFLD. Several studies have identified specific metabolomics signatures associated with different stage of the disease in NAFLD. (11) (12) (13) (14) (15) Moreover, evidence of interaction among the gut, liver, and blood metabolites has emerged in the recent years, suggesting that the gut-liver axis is an important component in the development of NAFLD. Indeed, compositional changes in gut microbiota have been proposed to mechanistically contribute to the progression of NAFLD. (16) (17) (18) (19) (20) (21) Several studies have shown a familial resemblance of the concentration of serum metabolites using twin and familial cohorts. (22) (23) (24) (25) (26) Furthermore, when combined within a twin study design, the heritability and shared gene-effect between serum metabolites and features of NAFLD allow further insight into the pathogenesis of NAFLD. If the gene regulation of a serum metabolite and features of NAFLD (e.g., hepatic steatosis and fibrosis) significantly overlap, then targeting specific nodal points in the metabolite pathway could have a major therapeutic impact in NAFLD. In addition, the metabolite would also be a useful biomarker for the screening of patients at risk of advanced stage of NAFLD.
The heritability of the serum metabolites associated with NAFLD has not been systematically assessed yet. Utilizing a well-characterized prospective cohort of community-dwelling twins and families, we aimed to investigate whether serum metabolites are heritable, whether serum metabolites have a shared gene-effect with hepatic steatosis and fibrosis, and if gut-microbiome derived metabolites mediate this shared gene-effect. We then validated the association between the gut-microbiome derived serum metabolites, and hepatic steatosis and advanced fibrosis in an independent validation cohort of prospectively recruited individuals with biopsyproven NAFLD.
Participants and Methods

STUDY PARTICIPANTS AND DESIGN OF THE DISCOVERY TWIN AND FAMILY COHORT
Study (ClinicalTrials.gov:NCT01643512) residing in southern California. This study included a total of 156 participants, 100 twins (50 twin pairs) including 37 pairs of monozygotic (MZ), 13 pairs of dizygotic (DZ) and 56 participants either siblings or parents-offspring recruited the University of California at San Diego (UCSD) NAFLD Research Center (6, 7, 27, 28) between December 2011 and January 2014. Please see Supporting Information for detailed visit research, inclusion and exclusion criteria.
STUDY PARTICIPANTS WITH NAFLD BIOPSY-PROVEN VALIDATION COHORT
The validation cohort included 156 participants prospectively recruited between October 2011 and May 2014 at the UCSD NAFLD Research Center. (6, 7, 27, 28) All patients with suspected NAFLD with a clinical indication for liver biopsy underwent a careful evaluation for other causes of hepatic steatosis and liver disease. This study was Health Insurance Portability and Accountability Act (HIPAA) compliant and was approved by the UCSD Institutional Review Board. Informed written consent was obtained from each participant before enrolling in the study. Please see Supporting Information for detailed inclusion and exclusion criteria.
PRIMARY OUTCOME
The primary outcome was the heritability and presence of shared gene-effect between serum metabolites and hepatic steatosis and fibrosis, and whether any of these metabolites were derived from the gut microbiome.
The secondary outcomes were the association between serum metabolites and hepatic steatosis assessed by magnetic-resonance-imaging proton-density-fat-fraction (MRI-PDFF) and hepatic fibrosis assessed by MR-elastography (MRE) in the twin and family cohort, and between gut microbiome derived serum metabolites and advanced fibrosis as defined by histologic stage three and four fibrosis.
We also assessed whether microbial metabolite were associated with liver fibrosis in both the discovery and validation cohort (fold-change of higher-MRE versus lower-MRE and of advanced versus no advanced fibrosis, respectively). Pathway reconstruction linking metabolites to human gut-microbiome species was performed. In the validation cohort, we then assessed whether gut microbiome derived metabolites were significantly correlated with the abundance of known gutmicrobiome species including species reported to be associated with advanced fibrosis. (19) 
MRI ASSESSMENT
MRI was performed at the UCSD MR3T Research Laboratory using the 3T research scanner (GE Signa EXCITE HDxt; GE Healthcare, Waukesha, WI). MRI-PDFF was used to measure hepatic steatosis and MRE was used to measure hepatic fibrosis. The details of the MRI protocol have been described by Permutt et al. (29) and Patel et al. (30) and are detailed in Supporting Information.
UNTARGETED METABOLOME PROFILING
Serum metabolite assessment was performed by Metabolon, Inc (Durham, NC). Samples were extracted and split into equal parts for analysis on the GC/MS and LC/MS/MS platforms. (31) Software was used to match ions to an in-house library of standards for metabolite identification and for metabolite quantitation by peak area integration. (32) For further details regarding serum metabolites data acquisition, please see Supporting Information.
GUT MICROBIOME SEQUENCING
The metagenomics analysis of the gut microbiome was performed using whole-genome shotgun sequencing of DNA extracted from stool samples in a subgroup of participant from the NAFLD biopsy-proven cohort (n 5 57). The detailed protocol for the DNA extraction, library preparation and sequencing has been described by Loomba et al. (19) STATISTICAL ANALYSIS
Data Preparation
Among 1,181 serum metabolites detected, 411 unnamed serum metabolites were excluded from the analysis. Metabolites for which there were more than 50% missing values, most definitely due to levels below the limits of detection (57 out of 770 and 69 out of 721 identified metabolites in the discovery and validation cohort, respectively), were also excluded from the analysis. For the remaining serum metabolites with fewer than 50% missing values, values were imputed to half of the observed minimum value for each metabolite assuming that the metabolites were under the limit of detection. In the twin and family cohort, if both twins in a pair had a missing value for the same metabolites, the missing values were left blank to avoid bias heritability estimates and the twin pairs were excluded from the heritability analysis. All the data were logtransformed prior to statistical analysis.
Data Analysis
Patients' demographic, anthropometric, clinical, and biochemical characteristics were summarized. Categorical variables were shown as counts and percentages, and associations were tested using a chi-squared test or Fisher's exact test. Normally distributed continuous variables were shown as mean (6 standard deviation), and differences between groups were analyzed using a two-independent samples t test or Wilcoxon-Mann-Whitney test.
Statistical comparison of serum metabolites between NAFLD and non-NAFLD groups and between individuals with the highest MRE measurements >4.17 kPa (corresponding to the ninety-fifth percentile) and the individuals with the lowest measurements <1.67 kPa (corresponding to the ninety-fifth percentile) were assessed using Welch's t tests, and Pearson correlation between serum metabolites and hepatic steatosis assessed by MRI-PDFF and hepatic fibrosis assessed by MRE or liver biopsy were performed followed by pairwise partial correlation conditional on age, sex, Hispanic ethnicity and obesity. To further explore familial effects within the dataset, a sampling permutation median P value was calculated for each metabolite by running 1,000 random selections of the dataset and calculating the P value for all compounds, followed by calculating the median P value for each metabolite from the 1,000 simulations. Statistical analyses were performed using ArrayStudio and the programs R. The False Discovery Rate using the Benjamini-Hochberg method was used to account for multiple testing.
The correlation between serum metabolites and the abundance of the gut microbiome bacterial species in a subgroup of unrelated participants from biopsy-proven NAFLD cohort was assessed using pairwise partial correlation coefficient and P values based on Pearson method conditional on age, sex calculated using R package ppcor.
Heritability Estimates and Share Gene-Effect
AE models were used to estimate the shared genetic determination (rG) and shared environmental determination (rE) between twin pairs in the subgroup of twins (n 5 100, 50 pairs) from the twin and family cohort. Detailed protocol have been described in previous studies; (6, 7) please see Supporting Information for additional information. The analyses were performed using OpenMx, a structural equation modeling software package for genetically informative data (http:// openmx.psyc.virginia.edu). Prior to the model fitting, the measures were adjusted for controlling age, gender, and ethnicity. Overall, AE models provided the best fits to the data. Consequently, the genetic effects estimated in these AE models refer to broad-sense heritability, reflecting the proportion of phenotypic variance accounted for by the combined effect of all genetic influences (A 1D).
SAMPLE SIZE ESTIMATION
Previous studies have reported that the mean heritability estimates of circulating metabolites was 0.53, ranging from 0.21 to 0.77 in a Netherlands twin cohort (22) and the median heritability estimates of serum metabolites was 0.49, ranging from 0.23 to 0.76 in a UK twins cohort. (24) We have also previously estimated the heritability of hepatic steatosis to be approximately 0.5.
(7) Therefore, we anticipated that the heritability of serum metabolite and hepatic steatosis with one another would be approximately 0.50. It has been shown that to detect an additive genetic component of 0.4-0.8 in an ACE model, approximately 36-74 twin pairs are needed to produce a power of 0.95 with an alpha value of 0.05. (33) Therefore, the 50 twin pairs included in this study would be adequate to assess the heritability and shared gene-effect of serum metabolites and hepatic steatosis in this cohort.
Results
CHARACTERISTICS OF THE DISCOVERY TWIN AND FAMILY COHORT
This study included a total of 156 participants, 100 twins (50 twin pairs) including 37 pairs of MZ, 13 pairs of DZ, and 56 participants either siblings or parents-offspring who underwent serum metabolites assessment, clinical evaluation and advanced MRI assessment. The mean (6 standard deviation) age and body mass index (BMI) was 46.3 years (6 19.8) and 26.6 kg/m 2 (6 6.0), respectively. The derivation of cohort is shown in Supporting Fig. S1 . The prevalence of NAFLD as defined by MRI-PDFF 5% was 23% (36/156) and the prevalence of hepatic fibrosis as defined by MRE 3 kPa was 18% (28/156). Detailed demographic, biochemical, and imaging data of subjects with NAFLD compared to subjects without NAFLD is provided in Table 1 .
SERUM METABOLITES ASSOCIATED WITH HEPATIC STEATOSIS AND FIBROSIS IN THE TWIN AND FAMILY COHORT
Among the 713 metabolites analyzed, 153 belonging to eight super pathways (amino-acid, peptide, energy, lipid, carbohydrate, nucleotide, cofactor and vitamins and xenobiotics) were significantly differentially expressed in individuals with NAFLD (MRI-PDFF 5%) compared to individuals without NAFLD (MRI-PDFF <5%) and 86 belonging to eight super pathways (amino-acid, peptide, energy, lipid, carbohydrate, nucleotide, cofactor and vitamins and xenobiotics) were significantly differentially expressed in individuals with the higher MRE measurements (>4.17 kPa, ninety-fifth percentile) compared to individual with lower MRE measurements (<1.61 kPa, fifth percentile), after assessment of the familial effect. Fig. S2 ).
SHARED GENE-EFFECTS BETWEEN SERUM METABOLITES AND HEPATIC STEATOSIS AND FIBROSIS
Among the 440 heritable serum metabolites identified, 170 serum metabolites had a significant shared gene-effect with hepatic steatosis, as measured by MRI-PDFF and 94 serum metabolites had a significant shared gene-effect with hepatic fibrosis as measured by MRE. Among them, 56 serum metabolites had a significant shared gene-effect with both hepatic steatosis and fibrosis (Fig. 1) . The fold-change of these 56 serum metabolites in individuals with NAFLD versus non-NAFLD and in individuals with higher MRE measurement versus lower MRE measurement are depicted in Fig. 2 . Interestingly, among these 56 serum metabolites, six metabolites had a microbial origin and derive potentially from the gut microbiome: 3-(4-hydroxyphenyl)lactate, N-formylmethionine, phenyllactate, mannitol, allantoine, N-(2-furoyl)glycine based upon the Human Metabolome Database http:// www.hmdb.ca/.
VALIDATION IN THE BIOPSY-PROVEN NAFLD COHORT
To further assess the statistical and clinical relevance of the 56 serum metabolites identified in the twin and family cohort, the association of the serum metabolites with advanced fibrosis was then validated in an independent validation cohort of 156 unrelated participants prospectively recruited with biopsy-proven NAFLD. The mean (6 standard deviation) age and BMI was 49.8 years (6 14.3) and 32.0 kg/m 2 (6 6.0) and the prevalence of advanced fibrosis (stage three to four) was 15% (23/156). Detailed demographic, biochemical, and histological data of subjects with advanced fibrosis compared to subjects without advanced fibrosis is provided in Table 2 .
3-(4-HYDROXYPHENYL)LACTATE GUT MICROBIOME-LINKED METABOLITES IS ASSOCIATED WITH LIVER FIBROSIS
Only six of the 56 serum metabolites identified in the twin and family cohort were confirmed and were significantly associated with advanced fibrosis in the validation cohort (Supporting Table S1 ). Among them, only one metabolite linked to the gut microbiome, 3-(4-hydroxyphenyl)lactate, was significantly associated with hepatic fibrosis in the validation and discovery cohort (Fig. 3) . The level of 3-(4-hydroxyphenyl)lactate was significantly correlated with hepatic fibrosis assessed by MRE in the discovery cohort and by liver biopsy in the validation cohort: r 5 0.25, P < 0.001, q 5 0.002 and r 5 0.25, P 5 0.002, q 5 0.018, respectively. Significant association between the level of 3-(4-hydroxyphenyl) lactate and gender and obesity was observed in both cohorts whereas no significant association was observed with Hispanic ethnicity (Supporting Table S2 ). The association between (Fig. 4A and 4B ). In addition, the mean (6 SD) scaled intensity of 3-(4-hydroxyphenyl)lactate was also significantly higher in individuals with NAFLD compared to individuals without NAFLD in the twin and family cohort (1.42 6 0.09 versus 1.00 6 0.03,fold-change: 1.42, P < 0.001) (Fig. 4B ). Finally, 3-(4-hydroxyphenyl)lactate was heritable, h 2 : 0.67, 95%CI: 0.434-0.814, P < 0.001 and had a significant shared gene-effect with both hepatic steatosis (R G : 0.57, 95%CI: 0.27-0.80, P < 0.001) and fibrosis (R G : 0.54, 95%CI: 0.036-1, P 5 0.036) after adjustment for age, sex and ethnicity (Fig. 4C) . 
3-(4-HYDROXYPHENYL)LACTATE LEVEL IS NOT ASSOCIATED WITH METFORMIN USE
As metformin is known to be associated with intestinal lactate generation, (34) we have further assessed the association between 3-(4-hydroxyphenyl)lactate and metformin use. There were 38 (24.4%) participants under metformin in the biopsy-proven NAFLD cohort and only 5 (3.2%) participants under metformin in the twin and family cohort. The level of 3-(4-hydroxyphenyl)lactate was not significantly different in participant under metformin compared to the participant without metformin: mean scaled intensity (6 SD) 1.04 (0.30) versus 1.05 (0.41), P 5 0.823, respectively. In addition, the association between the level of 3-(4-hydroxyphenyl)lactate and hepatic fibrosis remained significant when participants under metformin were excluded from the analysis in the validation and discovery cohort (r50.174, P 5 0.045 and r 5 0.215, P 5 0.027, respectively).
3-(4-HYDROXYPHENYL)LACTACTE IS DERIVED FROM THE HUMAN GUT MICROBIOME
The pathway reconstruction of 3-(4-hydroxyphenyl)-lactacte using KEGG PATHWAY Database have identified three main bacterial enzymes catalyzing both 3-(4-hydroxyphenyl)lactacte and phenyllactate: hydroxyphenylpyruvate reductase (HPPR), D-hydrogenase and cinnamoyl-CoA: phenyllactate CoA-transferase (FldA) (Supporting Fig. S4 ). In addition, the network reconstruction performed by crossing the bacterial species encoding for the three bacterial enzymes and the bacterial species belonging to the human gut microbiome identified 21 human gut microbiome bacterial species encoding for these three main enzymes, mainly Proteobacteria, Firmicutes (Fig. 5A) . Finally, the gut microbiome was analyzed in a subgroup of individuals from the biopsyproven NAFLD cohort using shotgun metagenomics sequencing. In these individuals, 3-(4-hydroxyphenyl)lactacte and phenyllactate were significantly correlated with the abundance of several bacterial species belonging only to Firmicutes, Bacteroidetes and Proteobacteria phyla, after adjustment for age and sex. Interestingly, among the bacterial species significantly correlated with phenyllactate and 3-(4-hydroxyphenyl)lactacte, 7 have been demonstrated to be associated with advanced fibrosis in NAFLD (19) : Bacteroides caccae, Clostridium sp, E. Coli, Firmicutes bacterium CAG110, Firmicutes bacterium CAG129, Firmicutes bacterium CAG176, Subdoligranulum sp (Fig. 5B) .
Discussion
MAIN FINDINGS
Utilizing a uniquely, well-characterized, discovery cohort of community-dwelling twins and families, and a validation cohort of patients with biopsy-proven NAFLD, we report the association between a gut microbiomederived serum metabolite, 3-(4-hydroxyphenyl) lactacte that has a statistically and clinically significant shared geneeffect with both hepatic steatosis and fibrosis. These results suggest a common genetic basis underlying the susceptibility towards NAFLD related fibrosis and 3-(4-hydroxyphenyl)lactacte pathway and their joint association with the gut microbiome. The shared gene-effect between NAFLD and this gut microbiome-derived metabolite provide insights into the emerging linkage between gut microbiome and NAFLD related fibrosis. It is plausible that targeting 3-(4-hydroxyphenyl)lactacte may influence shared genetic or epigenetic pathways associated with the development of NAFLD. However, further larger studies are needed to assess if there is a causal role of these bacterial derived metabolites as modifiers of disease severity rather than sole contributors of disease severity.
IN CONTEXT OF PUBLISHED LITERATURE
Studies have shown that both NAFLD (4, 5, 35) and serum metabolites are heritable traits. (22) (23) (24) (25) (26) In addition Spearman correlation between 3-(4-hydroxyphenyl)lactate and phenyllactate and the abundance of bacterial species in the human microbiome, only significant correlation are represented, *P value < 0.05, **P value < 0.01, ***P value < 0.001 after adjustment for age and sex. Framed bacterial species have been reported to be significantly associated with the presence of advanced fibrosis. (19) we have demonstrated significant shared gene-effects between hepatic steatosis and metabolic risk factors. (6, 7) We build on the results of these studies to show additional heritability and shared gene-effect between hepatic steatosis and fibrosis and serum metabolites. In this study, we report similar heritability estimates of serum metabolites as previous studies using a twin and family model. (22) (23) (24) (25) (26) In addition, we have identified an amino-acid belonging to tyrosine metabolism, 3-(4-hydroxyphenyl)lactacte, significantly associated with both hepatic steatosis and fibrosis. This result is in line with previous studies showing differences in amino-acid pathway associated with features of NAFLD and underlie the potential role of amino-acids in the development and progression of NAFLD. (12) (13) (14) (15) We report a significant correlation between the amino-acid 3-(4-hydroxyphenyl)lactacte and the abundance of several gut microbiome species. Likewise, a recent study by Liu et al. has shown a link between intestinal microbiota alterations and circulating amino acids in obesity. (36) In recent years, the gut-liver axis has emerged as an important component in the development of NAFLD. Compositional changes in gut microbiota have been proposed to mechanistically contribute to the progression of NAFLD. (16) (17) (18) (19) (20) A higher proportion of Gramnegative bacterial species in the gut microbiome has been reported in NAFLD (17) and significant changes in the gut microbiome have been linked to NAFLD, NASH and NASH-related liver fibrosis. (37, 38) We report significant correlation between the abundance of several bacterial species in the gut microbiome and the circulating level of 3-(4-hydroxyphenyl)lactacte, including bacterial species associated with advanced fibrosis in a previous study. (19) Interestingly, the abundance of E. Coli was positively correlated with the circulating level of 3-(4-hydroxyphenyl)lactacte and phenyllactate in this study. In line with this observation, E. Coli has been reported to produce hydroxyphenyllactate and phenyllactate in vitro. (39) In addition, we have previously demonstrated that E. Coli was significantly increased in advanced fibrosis. (19) These data suggest an association between gut-microbiome alteration, the circulating level of 3-(4-hydroxyphenyl)lactacte and hepatic fibrosis in NAFLD. Likewise, intestinal dysbiosis has been shown to be associated with changes in serum metabolites potentially involved in NAFLD pathogenesis. Reduced bacterial diversity in NAFLD patients has been associated with disrupted bile acids profiles in serum and feces, potentially due to the loss of gut microbiota members involved in the generation of secondary bile acids. (40) In addition, certain species of the gut microbiota can metabolize choline to trimethylamine which is associated with the presence and severity of NAFLD. (41) Further studies are needed to determine whether 3-(4-hydroxyphenyl)lactacte plays a causal role in the development of hepatic steatosis and fibrosis. Limited data are available regarding the potential molecular function of 3-(4-hydroxyphenyl)lactacte. Although, a study by Beloborodova and colleagues have suggested that hydroxyphenyllactate may decrease the production of reactive oxygen species in mitochondria and neutrophils in rodents in vitro, (39) these data need to be confirmed in vivo and in humans. Finally, further studies are needed to determine the mechanism involved in the cross-talk with gut-microbiome derived metabolites to induce liver injury and to affect disease progression in NAFLD (Fig. 6) .
Our results suggest a link between genetics and the gut microbiome-derived metabolite 3-(4-hydroxyphenyl)lactacte in the heritability of NAFLD. Previous studies have demonstrated that the gut microbiome is shared among families. (42, 43) Moreover, Goodrich et al. have recently demonstrated that features of the gut microbiome are inherited and determined via the host genotype using a genome-wide association analysis in a twin model. (43) Furthermore, metabolomics profiling coupled with GWAS has identified several single nucleotide polymorphisms (SNPs) at various loci associated with human blood metabolites accounting for a significant variance of the metabolites traits. (23) (24) (25) 44) However, these studies did not assess the association between the gut microbiome and serum metabolite. It is possible that inherited features of the gut microbiome accounts for the heritability of the gut microbiome derived metabolites. However, further studies are needed to determine the genetic association between gut microbiome alteration, serum metabolites and NAFLD.
STRENGTHS AND LIMITATIONS
There are several notable strengths in this study, including the use of two independent and complementary well-characterized prospective cohorts in which conditions such as excessive alcohol use, steatogenic therapies, viral hepatitis, and secondary causes of steatosis were systematically excluded. The twin and family cohort allows for the assessment of the heritability estimates and shared gene-effects using accurate and reproducible non-invasive imaging biomarker for the quantification of hepatic steatosis and fibrosis. The biopsy-proven NAFLD cohort allows to validate and confirm the relevance of the findings using the liver biopsy which remains the gold standard for the diagnosis of liver fibrosis.
However, we acknowledge the following limitations; this cross-sectional study design only allowed capturing a snapshot of metabolomics across the different features of NAFLD. Therefore it is not possible to determine whether 3-(4-hydroxyphenyl)lactacte is a causal factor in the pathogenesis of NAFLD. In addition, human cells only produce L-form of lactate whereas bacterial species have the enzymatic capacity to produce both isoform (45) and it was not possible to distinguish the two stereoisomeric of 3-(4-hydroxyphenyl)lactacte using the standard mass spectroscopy in this study. Finally, although the association between 3-(4-hydroxyphenyl)-lactacte and hepatic fibrosis was significant after adjustment for age, sex, obesity and Hispanic ethnicity, potential other confounding factors such as diet could not be excluded.
Further longitudinal studies are needed to determine the role of 3-(4-hydroxyphenyl)lactacte in the development of NAFLD and whether 3-(4-hydroxyphenyl)-lactacte is a reliable biomarker associated with longitudinal changes in hepatic steatosis and fibrosis.
IMPLICATIONS FOR FUTURE STUDY
In this proof of concept study, we report the discovery of a gut microbiome-linked serum metabolite, 3-(4-hydroxyphenyl)lactacte that has a statistically and clinically significant shared gene-effect with both hepatic steatosis and fibrosis using two independent cohorts. Further studies with larger sample sizes are needed to determine the precise genetics mechanism underlying the relationship between the gut microbiome, 3-(4-hydroxyphenyl)lactacte and NAFLD. Future studies from independent cohorts are needed to validate these findings and assess if 3-(4-hydroxyphenyl)lactacte could be a useful non-invasive biomarker of gut microbiome involvement in NAFLD related fibrosis and whether it could be used for monitoring the targeted therapeutic response when modulating the microbiome to affect hepatic fibrosis in NAFLD.
